Intervet introduces Continuum Feline HCP vaccine with three-year immunity

MILLSBORO, DEL. — Intervet Inc. announces the introduction of Continuum® Feline HCP vaccine with a three-year duration of immunity against rhinotracheitis caused by herpesvirus-1 (FHV-1), calicivirus (FCV) and panleukopenia (FPV).

Continuum Feline HCP is the first feline vaccine approved for three-year protection against these diseases, according to the company.

This product provides flexibility to customize feline vaccination protocols, the company adds.

With a non-adjuvanted formulation, Continuum Feline HCP provides long-term safety for cats 8 weeks of age and older and may reduce the risk of adverse events, the company reports.

Study results included:

• Rhinotracheitis: Statistically significant reduction in virulent FRV-associated clinical signs (P=0.005).

• Calicivirus: 100 percent protection against oral ulcerations associated with FCV infection.

• Panleukopenia: 100 percent protection against disease associated with virulent FPV challenge.

For fastest response, call

(800) 441-8272

www.continuum3.com